Starting from the success of anti-CTLA-4 antibody in malignant melanoma, targeted immunotherapy has become one of the effective strategies for anti-tumor therapy, and raised a new wave of research on tumor immunotherapy. In the field of lung cancer, a series of clinical studies on immune-targeted drugs have been carried out aboard, nivolumab, pembrolizumab and atezolizumab have been approved for the treatment of lung cancer, which rewrite the history of lung cancer treatment. In China, clinical studies on immune-targeted drugs for lung cancer have also been developed. The present study mainly analyzed and investigated the current situation, gap and future innovation of the research on anti-tumor immunity of lung cancer in China.
从抗CTLA-4抗体Ipilimumab在恶性黑色素瘤中获得成功开始，靶向免疫检查点的治疗成为抗肿瘤治疗的有效策略之一，掀起了肿瘤免疫治疗研究的新浪潮。在肺癌领域，国外开展了一系列免疫靶向药物的临床研究，Nivolumab、Pembrolizumab和Atezolizumab相继被批准用于肺癌的治疗，改写了肺癌治疗历史。在中国，也相继开展了肺癌免疫靶向药物的临床研究，本文主要对中国肺癌免疫研究的现状、差距和未来如何创新进行了分析和探讨。.
Keywords: Checkpoint; Immunotherapy; Lung neoplasms.